Tim Cortese

The FDA has approved zenocutuzumab for the treatment of patients with NRG1 fusion-positive cholangiocarcinoma after progression on or after systemic therapy.

ASCO has recommended expanded eligibility for independent oncology practices and stricter oversight to ensure savings benefit for underserved patients.

Patients who received human milk oligosaccharide demonstrated preserved Shannon Diversity index compared with control.

Tovecimig plus paclitaxel yielded a median OS of 8.9 months vs 9.4 months with control in second-line biliary tract cancer in the phase 2/3 COMPANION-002 trial.

According to Asfar Azmi, PhD, results from the study showed that the PCNA inhibitor AOH1996 was synergistic with KRAS inhibitors of all classes.

Asfar Azmi, PhD, discussed a poster from the AACR Annual Meeting that investigated the NAMPT inhibitor RPT-E-037 and the pan-RAS inhibitor daraxonrasib in pancreatic cancer.

The new guidelines address 11 key clinical questions for optimizing communication between clinicians and patients with cancer.

Among all patients with gynecologic malignancies who received a formal radiation cystitis diagnosis, 87.5% received treatment and 56.0% were referred to a urologic specialist.

Across both pretreated cervical cancer and PROC populations, no new safety signals and low rates of treatment discontinuation were observed with DB-1311/BNT324.

The SISTER trial was the first national randomized trial to demonstrate significantly improved outcomes for black women with endometrial cancer.

A retrospective review showed an ORR of 42.9% in radiated fields vs 35.7% in non-radiated fields among patients with cervical cancer who received tisotumab vedotin.

The incidence rates of breast cancer and colorectal cancer have been on the rise in patients under 50 years for the past several years.

ONCOLOGY has identified FDA approvals that have affected the oncology treatment paradigm over the last 40 years.

In the phase 3 KEYNOTE-590 trial, the PD-L1 IHC 22C3 pharmDx (Code SK006) companion diagnostic was used to evaluate PD-L1 status in tumor specimens.

Investigators highlighted that emotional and cognitive consequences of beliefs were primarily negative among caregivers of children with cancer.

Data from the ROSELLA trial support the approval of relacorilant plus nab-paclitaxel in this ovarian cancer population.

The MyChoice CDx was approved based on its performance determining HRD status and stratifying patients in the phase 3 PRIMA trial.

In each decade since the launch of the journal ONCOLOGY, cancer care has evolved, and with it the finances and costs associated with these improving treatments.

The future of radiation oncology will be largely affected by artificial intelligence and genomics, according to Sheila D. Rege, MD, FACRO.

Marc Lehrer Greenwald, MD, spoke with CancerNetwork® about how North Shore University Hospital treats young patients with colorectal cancer.

Marwan G. Fakih, MD, discussed many of the factors he considers when deciding on a treatment for a patient with metastatic colorectal cancer.

Updated results from the phase 3 KEYNOTE-B96 trial revealed that pembrolizumab plus paclitaxel with or without bevacizumab improved OS in all comers.

Loretta Nastoupil, MD, reflected on some of the differences between practicing in a rural, community cancer center compared with a larger institutional center.

The FDA approved zongertinib in HER2-mutated NSCLC as part of its Commissioner's National Priority Voucher pilot program.

The guidelines offer best practices for diagnoses, classification, systemic treatment, radiation therapy, and surgery for patients with RMS.

The role of bispecific antibodies in mantle cell lymphoma treatment remains unclear, and they are not readily available in community sites, according to Tycel Phillips, MD.

Dominique Rash, MD, presented several cases of patients with inoperable endometrial cancer at the 2026 ACRO Summit.

Michael Buckstein, MD, spoke with CancerNetwork about the benefits of using radiation to treat celiac plexus-associated pain.

Theranostics, a technique that combines traditional medication with diagnostics, is “limitless,” according to Brandon Mancini, MD, MBA, FACRO.

According to investigators of the phase 3 SCOT trial, most patients with colon and rectal cancer should be receiving only 3 months of adjuvant treatment.